Enlivex Therapeutics (FRA:1BT) Debt-to-Equity : 0.03 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Enlivex Therapeutics Debt-to-Equity?

Enlivex Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.32 Mil. Enlivex Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.63 Mil. Enlivex Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €27.59 Mil. Enlivex Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Enlivex Therapeutics's Debt-to-Equity or its related term are showing as below:

FRA:1BT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.03 Max: 0.09
Current: 0.03

During the past 12 years, the highest Debt-to-Equity Ratio of Enlivex Therapeutics was 0.09. The lowest was 0.01. And the median was 0.03.

FRA:1BT's Debt-to-Equity is ranked better than
82.16% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs FRA:1BT: 0.03

Enlivex Therapeutics Debt-to-Equity Historical Data

The historical data trend for Enlivex Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Debt-to-Equity Chart

Enlivex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.07

0.09

0.03

Enlivex Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.09	0.09	0.10	0.12	0.03

Competitive Comparison of Enlivex Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Enlivex Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enlivex Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Enlivex Therapeutics's Debt-to-Equity falls into.

Enlivex Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Enlivex Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.317	+	0.629)	/	27.587
	=	0.03

Enlivex Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.317	+	0.629)	/	27.587
	=	0.03

Enlivex Therapeutics (FRA:1BT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Enlivex Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Enlivex Therapeutics (FRA:1BT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (FRA:1BT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ENLV:USA ENLV:Israel

Address

14 Einstein Street, Nes Ziona, ISR, 7403618

Website

https://www.enlivex.com

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics (FRA:1BT) Headlines

No Headlines